---
document_datetime: 2023-09-21 17:07:44
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/arepanrix-epar-all-authorised-presentations_en.pdf
document_name: arepanrix-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8104704
conversion_datetime: 2025-12-23 07:49:37.309591
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| EU Number                                                                 | Invented name                                                             | Strength                                                                  | Pharmaceutical                                                            | Route of Administration                                                   | Packaging                                                                 | Content (concentration)                                                   | Package size                                                              |
|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|
| EU/1/10/624/001                                                           | Arepanrix                                                                 | -- 1                                                                      | Form Suspension and emulsion for emulsion for injection                   | Intramuscular use                                                         | suspension (H1N1): vial (glass); emulsion (adjuvant): vial (glass)        | suspension: 2.5 ml; emulsion: 2.5 ml                                      | 50 vials (suspension) + 2 x 25 vials (emulsion)                           |
| longer authorised _ _1 3.75 µg HA After mixing, 1 dose (0.5 ml) contains: | longer authorised _ _1 3.75 µg HA After mixing, 1 dose (0.5 ml) contains: | longer authorised _ _1 3.75 µg HA After mixing, 1 dose (0.5 ml) contains: | longer authorised _ _1 3.75 µg HA After mixing, 1 dose (0.5 ml) contains: | longer authorised _ _1 3.75 µg HA After mixing, 1 dose (0.5 ml) contains: | longer authorised _ _1 3.75 µg HA After mixing, 1 dose (0.5 ml) contains: | longer authorised _ _1 3.75 µg HA After mixing, 1 dose (0.5 ml) contains: | longer authorised _ _1 3.75 µg HA After mixing, 1 dose (0.5 ml) contains: |

AS03 adjuvant composed of squalene (10.69 milligrams), DLα -tocopherol (11.86 milligrams) and polysorbate 80 (4.86 milligrams)

Medicinal product no longer authorised